Disc Medicine Inc Ordinary Shares IRON

Morningstar Rating
$75.14 −0.97 (1.27%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

IRON is trading at a LOCK|Nlzvz premium.
Price
$76.11
Fair Value
LOCK|.#f@^%&
Uncertainty
LOCK|#j
1-Star Price
LOCK|J.>$t$NW^
5-Star Price
LOCK|.ZbmL^Td
Economic Moat
LOCK|^Q>
Capital Allocation
—

News

Trading Information

Previous Close Price
$76.11
Day Range
$74.54–77.01
52-Week Range
$40.00–99.50
Bid/Ask
$59.99 / $80.00
Shares Outstanding
45.54M
Market Cap
$3.42B
Volume/Avg
561,645 / 933,751

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Core
Total Number of Employees
173

Valuation

Metric
IRON
Price/Earnings (Normalized)
—
Price/Book Value
4.80
Price/Sales
—
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
IRON
Quick Ratio
19.87
Current Ratio
20.30
Interest Coverage
−61.10
Quick Ratio
IRON

Profitability

Metric
IRON
Return on Assets (Normalized)
−28.37%
Return on Equity (Normalized)
−31.61%
Return on Invested Capital (Normalized)
−32.11%
Return on Assets
IRON

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|$d^>vYgLOCK|ft#^$131B
Regeneron Pharmaceuticals Inc
REGN
LOCK|TRyx#GYLOCK|P$Hk$95B
Moderna Inc
MRNA
LOCK|x><G!^LOCK|rh$79B
argenx SE ADR
ARGX
LOCK|T&G$kcLOCK|$^?$59B
BeOne Medicines Ltd ADR
ONC
LOCK|%?g^S>RLOCK|x<$45B
Royalty Pharma PLC Class A
RPRX
LOCK|H#>>!gHLOCK|>&wCw$30B
Incyte Corp
INCY
LOCK|H!ww@LRLOCK|F#$23B
BioNTech SE ADR
BNTX
LOCK|^D%@?N^LOCK|<>j$20B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|X#c?$$WLOCK|<d#r$19B
BridgeBio Pharma Inc
BBIO
LOCK|F&#$m!^LOCK|C>@$15B

Sponsor Center